IIM
MCID: MYS005
MIFTS: 54

Myositis (IIM)

Categories: Genetic diseases, Infectious diseases, Muscle diseases, Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Myositis

MalaCards integrated aliases for Myositis:

Name: Myositis 57 12 75 29 55 6 43 44 15 17 72 33
Myopathy, Familial Idiopathic Inflammatory; Iim 57
Myopathy, Familial Idiopathic Inflammatory 57
Inflammatory Disorder of Muscle 12
Iim 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
myositis:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:633
OMIM 57 160750
MeSH 44 D009220
NCIt 50 C27578
SNOMED-CT 68 26889001
MedGen 42 C0027121
UMLS 72 C0027121

Summaries for Myositis

MedlinePlus : 43 Myositis means inflammation of the muscles that you use to move your body. An injury, infection, or autoimmune disease can cause it. Two specific kinds are polymyositis and dermatomyositis. Polymyositis causes muscle weakness, usually in the muscles closest to the trunk of your body. Dermatomyositis causes muscle weakness, plus a skin rash. Other symptoms of myositis may include Fatigue after walking or standing Tripping or falling Trouble swallowing or breathing Doctors may use a physical exam, lab tests, imaging tests and a muscle biopsy to diagnose myositis. There is no cure for these diseases, but you can treat the symptoms. Polymyositis and dermatomyositis are first treated with high doses of a corticosteroid. Other options include medications, physical therapy, exercise, heat therapy, assistive devices, and rest. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Myositis, also known as myopathy, familial idiopathic inflammatory; iim, is related to granulomatous myositis and myositis fibrosa, and has symptoms including muscle weakness, myoclonus and myalgia. An important gene associated with Myositis is CAPN3 (Calpain 3). The drugs Oseltamivir and Telbivudine have been mentioned in the context of this disorder. Affiliated tissues include lung, skeletal muscle and bone, and related phenotypes are myositis and proximal muscle weakness

Disease Ontology : 12 A myopathy characterized by muscle inflammation.

Wikipedia : 75 Myositis is inflammation or swelling of the muscles. Injury, medicines, infection, or an immune disorder... more...

More information from OMIM: 160750

Related Diseases for Myositis

Diseases in the Myositis family:

Bacterial Myositis Viral Myositis

Diseases related to Myositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 904)
# Related Disease Score Top Affiliating Genes
1 granulomatous myositis 34.3 TTN PIK3C2A
2 myositis fibrosa 33.9 PIK3C2A MB
3 proliferative fasciitis 30.9 SERPINA3 MB
4 gas gangrene 30.7 PIK3C2A MB DMD
5 compartment syndrome 30.7 PIK3C2A MB CHKB
6 miyoshi muscular dystrophy 30.5 TTN DYSF DMD CAPN3
7 muscular dystrophy, becker type 30.5 PIK3C2A DYSF DMD
8 limb-girdle muscular dystrophy 30.4 TTN DYSF DMD CAPN3
9 isolated hyperckemia 30.4 DMD CAPN3
10 anterior compartment syndrome 30.3 PIK3C2A DYSF
11 tibial muscular dystrophy 30.3 TTN CAPN3
12 autosomal recessive limb-girdle muscular dystrophy type 2a 30.2 TTN DYSF CAPN3
13 muscular dystrophy-dystroglycanopathy , type c, 5 30.2 TTN DYSF CAPN3
14 localized lipodystrophy 30.2 DYSF DMD
15 muscular dystrophy, limb-girdle, autosomal recessive 2 30.2 TTN DYSF CAPN3
16 muscular dystrophy 30.2 TTN PIK3C2A MSTN DYSF DMD CHKB
17 interstitial myocarditis 30.1 PIK3C2A MB
18 dysferlinopathy 29.9 DYSF CAPN3
19 muscular dystrophy, congenital, lmna-related 29.9 TTN DMD CHKB
20 neuroleptic malignant syndrome 29.8 PIK3C2A MB CHKB
21 anuria 29.2 PIK3C2A MB
22 muscular disease 29.0 TTN PIK3C2A MSTN MB IFIH1 DYSF
23 inclusion body myositis 12.9
24 congenital disorder of glycosylation, type iim 12.7
25 myositis ossificans 12.6
26 fibrodysplasia ossificans progressiva 12.5
27 focal myositis 12.5
28 infective myositis 12.4
29 viral myositis 12.4
30 bacterial myositis 12.4
31 fungal myositis 12.4
32 overlap myositis 12.4
33 parasitic myositis 12.4
34 idiopathic eosinophilic myositis 12.4
35 idiopathic inflammatory myopathy 12.3
36 juvenile overlap myositis 12.2
37 obsolete: granulomatous myositis 12.1
38 dermatomyositis 12.0
39 slc35a2-congenital disorder of glycosylation 12.0
40 pyomyositis 12.0
41 myopathy 11.8
42 orbital plasma cell granuloma 11.8
43 polymyositis 11.7
44 necrotizing autoimmune myopathy 11.6
45 influenza 11.5
46 antisynthetase syndrome 11.5
47 childhood type dermatomyositis 11.5
48 proteasome-associated autoinflammatory syndrome 1 11.5
49 foot drop 11.5
50 welander distal myopathy, swedish type 11.5

Graphical network of the top 20 diseases related to Myositis:



Diseases related to Myositis

Symptoms & Phenotypes for Myositis

Human phenotypes related to Myositis:

32
# Description HPO Frequency HPO Source Accession
1 myositis 32 HP:0100614
2 proximal muscle weakness 32 HP:0003701

Symptoms via clinical synopsis from OMIM:

57
Muscle:
myositis
proximal muscle weakness

Clinical features from OMIM:

160750

UMLS symptoms related to Myositis:


muscle weakness, myoclonus, myalgia, back pain, torticollis, sciatica, muscle cramp, muscle rigidity, muscle spasticity

MGI Mouse Phenotypes related to Myositis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.23 APP CAPN3 CHKB DMD DYSF MB

Drugs & Therapeutics for Myositis

Drugs for Myositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 188)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
2
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
3
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
4
Simvastatin Approved Phase 4 79902-63-9 54454
5
Ezetimibe Approved Phase 4 163222-33-1 150311
6
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
7
Atorvastatin Approved Phase 4 134523-00-5 60823
8
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
9
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
10
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
11
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
12 Anti-Infective Agents Phase 4
13 Anti-HIV Agents Phase 4
14 Anti-Retroviral Agents Phase 4
15 Antiviral Agents Phase 4
16 Nucleic Acid Synthesis Inhibitors Phase 4
17 Reverse Transcriptase Inhibitors Phase 4
18 Central Nervous System Depressants Phase 4
19 Folate Phase 4
20 Vitamin B9 Phase 4
21 Vitamin B Complex Phase 4
22 Protective Agents Phase 4
23 Micronutrients Phase 4
24 Trace Elements Phase 4
25 Vitamins Phase 4
26 Nutrients Phase 4
27 Antioxidants Phase 4
28 Ezetimibe, Simvastatin Drug Combination Phase 4
29 Liver Extracts Phase 4
30 Vasodilator Agents Phase 4
31 Vitamin B3 Phase 4
32 Nicotinic Acids Phase 4
33 Lipid Regulating Agents Phase 4
34 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
35 Hypolipidemic Agents Phase 4
36 Anticholesteremic Agents Phase 4
37 Antimetabolites Phase 4
38
Sirolimus Approved, Investigational Phase 2, Phase 3 53123-88-9 6436030 5284616 46835353
39
Everolimus Approved Phase 2, Phase 3 159351-69-6 6442177 70789204
40
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
41
Infliximab Approved Phase 2, Phase 3 170277-31-3
42
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
43
leucovorin Approved Phase 3 58-05-9 143 6006
44
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
45
Lenograstim Approved, Investigational Phase 3 135968-09-1
46
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
47
belimumab Approved Phase 2, Phase 3 356547-88-1 5957 10451420
48
Abatacept Approved Phase 3 332348-12-6 10237
49
Sodium citrate Approved, Investigational Phase 3 68-04-2
50
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0

Interventional clinical trials:

(show top 50) (show all 155)
# Name Status NCT ID Phase Drugs
1 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in SLE Patients With Corticosteroid Therapy and High LDL Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
2 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
3 A Randomized, Prospective, Multicenter, Open-label Study to Evaluate the Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir in HBeAg-positive Chronic Hepatitis B Patients Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
4 Effects of High Dose Simvastatin vs. Atorvastatin on Baseline Lipoprotein Profiles, Apo-A-1 and C Reactive Protein Unknown status NCT00736463 Phase 4 Simvastatin;Atorvastatin 80 mg
5 Rho-kinase in Patients With Atherosclerosis: Effects of Statins A Randomized Clinical Trial Comparing Ezetimibe/Simvastatin and Simvastatin Completed NCT00560170 Phase 4 Simvastatin (Zocor);10mg/10mg of Ezetimibe/Simvastatin (Vytorin)
6 The Effects of Melatonin on Elevated Liver Enzymes During Statins Treatment Completed NCT03121521 Phase 4 Melatonin 10 mg;Placebo
7 Magnetic Resonance Characterization of Carotid Atherosclerotic Plaque in Vivo: Effect of High Density Lipoprotein Elevation on Plaque Morphology Completed NCT00307307 Phase 4 Niacin/simvastatin compared to simvastatin alone at 2 doses
8 Double Blind, Prospective Randomized, Crossover Study of Patients With Muscle Complaints on Statin Therapy Terminated NCT00127335 Phase 4 cellulose placebo vs. atorvastatin
9 Anakinra in Patients With Refractory Idiopathic Inflammatory Myopathies Completed NCT01165008 Phase 2, Phase 3 Anakinra
10 A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Dose-finding, Pivotal, Phase 2b/3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous BYM338 at 52 Weeks on Physical Function, Muscle Strength, and Mobility and Additional Long Term Safety up to 2 Years in Patients With Sporadic Inclusion Body Myositis Completed NCT01925209 Phase 2, Phase 3 BYM338/bimagrumab;Placebo
11 Safety and Tolerability Trial of Arimoclomol for Sporadic Inclusion Body Myositis Completed NCT00769860 Phase 2, Phase 3 Arimoclomol
12 Étude de l'Effet de la Rapamycine Sur la Force Musculaire et la réponse Immunitaire au Cours de la Myosite à Inclusions: étude RAPAMI" Completed NCT02481453 Phase 2, Phase 3 Rapamycin;Placebo
13 An Open Trial With TNF Blockade With Infliximab (Remicade®), in Patients With Chronic Inflammatory Myopathies Completed NCT00443222 Phase 2, Phase 3 Infliximab
14 An Open-label, Long-term Study to Evaluate the Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT02250443 Phase 2, Phase 3 BYM338 (Bimagrumab)
15 Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT02573467 Phase 3 Bimagrumab;Placebo
16 A Prospective, Randomised, Assessor-blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With Polymyositis and Dermatomyositis. Completed NCT00651040 Phase 3 Prednisone;Methotrexate
17 Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms Completed NCT01032993 Phase 2, Phase 3
18 Effect of 80-mg Atorvastatin on Myocardial Edema Following Coronary Artery Bypass Surgery in Relation With Follistatin-Like Protein-1 Completed NCT02901379 Phase 3 Atorvastatin 80mg;Atorvastatin 10mg
19 High Dose Cyclophosphamide for Treatment of Systemic Sclerosis (Scleroderma) Completed NCT00501995 Phase 3 IV Cyclophosphamide
20 A Double Blind Randomized Control Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Completed NCT01553981 Phase 3 Tadalafil;Placebo
21 High-dose Simvastatin for Aneurysmal Subarachnoid Haemorrhage: Is it Better? Completed NCT01077206 Phase 2, Phase 3 Simvastatin
22 Belimumab for Maintenance Therapy in Idiopathic Inflammatory Myositis Recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
23 A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC With Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (IIM) Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
24 A Randomized, Double Blind Controlled Trial Comparing Rituximab Against Intravenous Cyclophosphamide in Connective Tissue Disease Associated Interstitial Lung Disease Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
25 Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis ("ProDERM Study") Active, not recruiting NCT02728752 Phase 3 Octagam 10%
26 MOVE TRIAL: A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) Active, not recruiting NCT03312634 Phase 3 Palovarotene
27 An Open-label, Non-randomized Trial to Investigate the Efficacy and Safety of Early Versus Delayed Start of Arimoclomol in Patients With Sporadic Inclusion Body Myositis Who Have Completed the IBM4809 Trial Enrolling by invitation NCT04049097 Phase 3 Arimoclomol
28 Intraorbital Injection Versus Oral Steroid in Patients With Anterior Idiopathic Orbital Inflammation: A Randomized Clinical Trial Not yet recruiting NCT03958344 Phase 3 Prednisolone;Triamcinolone + Betamethason
29 Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease : Multicentric Randomized Phase III Trial Not yet recruiting NCT03770663 Phase 3 Cyclophosphamide and azathioprine;Tacrolimus
30 Efficacy of Denosumab and Zoledronic Acid in the Treatment of Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density: a Prospective Controlled Trial Not yet recruiting NCT04034199 Phase 3 Denosumab;Zoledronic Acid
31 A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT01423110 Phase 2
32 A Phase 2 Open-label Study to Evaluate the Long-term Safety of Sifalimumab in Adult Subjects With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
33 Effects of a T Cell-Depleting Monoclonal Antibody, Alemtuzumab, in Patients With Inclusion Body Myositis: A Pilot Clinicopathological Study Completed NCT00079768 Phase 2 Alemtuzumab (Campath)
34 The Efficacy of High-Dose Intravenous Immunoglobulin in Patients With Inflammatory Myopathies: A Three Month Randomized Trial With Option for Cross-Over Completed NCT00001261 Phase 2 Gamma Globulin
35 Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM) Completed NCT00106184 Phase 2 Rituximab;Placebo
36 FORCE: Rituximab (CD 20+-B Cell-depleting Monoclonal Antibody) for the Treatment of Refractory Inflammatory Myopathies With Specific Antibodies and Refractory Myasthenia Gravis Completed NCT00774462 Phase 2 Rituximab
37 Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors. Completed NCT00519363 Phase 1, Phase 2 atorvastatin
38 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP) Completed NCT02190747 Phase 2 Palovarotene;Placebo
39 The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers Completed NCT00805870 Phase 2 Lovaza (omega-3-acid ethyl esters);Wheat Germ Oil
40 A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 or Placebo When Coadministered With Fenofibrate in Subjects With Combined Hyperlipidemia Completed NCT00813527 Phase 2 Lapaquistat acetate and fenofibrate;Fenofibrate
41 Novel Drug Delivery of Sodium Thiosulfate for Calcinosis Associated With Adult and Juvenile Dermatomyositis Completed NCT01572844 Phase 2 Sodium thiosulfate
42 Open Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or Polymyositis Completed NCT01906372 Phase 2 Adrenocorticotropic Hormone Gel
43 A Pilot Study of the Role of Methimazole in Patients With Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2 methimazole
44 Phase II Clinical Trial to Examine the Efficacy and Safety of Dutasteride in Patients With Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) Completed NCT00303446 Phase 2 Dutasteride;Placebo
45 A Randomized, Third-Party-Blind, Placebo-Controlled Pilot Study of the Effect of h5G1.1-mAb on Dermatomyositis Patients Completed NCT00005571 Phase 2 h5G1.1-mAb
46 A Randomized, Double-Blind, Placebo-Controlled Trial of Infliximab in Patients With Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2 Infliximab
47 A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome Recruiting NCT03215927 Phase 2 Abatacept
48 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Recruiting NCT02043548 Phase 2 tocilizumab;placebo
49 A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis Recruiting NCT04033926 Phase 2 KZR-616;Placebo
50 STAT (STatins and Aspirin in Trauma) Trial: A Phase II, Pragmatic, Prospective, Randomized, Double-blind, Adaptive Clinical Trial Examining the Efficacy of Statins and Aspirin in the Reduction of Acute Lung Injury and Venous Thromboembolism in Patients With Fibrinolysis Shutdown Recruiting NCT02901067 Phase 2 Aspirin and Rosuvastatin;Placebo (for Aspirin and Rosuvastatin)

Search NIH Clinical Center for Myositis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Carisoprodol
Chlorphenesin
chlorphenesin carbamate
Chlorzoxazone
cyclobenzaprine
Cyclobenzaprine hydrochloride
metaxalone
Methocarbamol
Orphenadrine
Orphenadrine Citrate
Orphenadrine Hydrochloride
tizanidine
tizanidine hydrochloride

Cochrane evidence based reviews: myositis

Genetic Tests for Myositis

Genetic tests related to Myositis:

# Genetic test Affiliating Genes
1 Myositis 29

Anatomical Context for Myositis

MalaCards organs/tissues related to Myositis:

41
Lung, Skeletal Muscle, Bone, T Cells, Testes, Skin, Heart

Publications for Myositis

Articles related to Myositis:

(show top 50) (show all 8929)
# Title Authors PMID Year
1
Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. 38 8
9550481 1998
2
Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis/dermatomyositis. 38 17
31096460 2019
3
Unusual case of lower back pain-piriformis myositis: a case report and literature review. 38 17
31182987 2019
4
Cutaneous Ulcerations in Anti-MDA5 Dermatomyositis. 17
31365803 2019
5
Increased BACE1 mRNA and noncoding BACE1-antisense transcript in sporadic inclusion-body myositis muscle fibers--possibly caused by endoplasmic reticulum stress. 9 38
20236612 2010
6
Gemfibrozil-induced myositis in a patient with normal renal function. 9 38
19934390 2010
7
Sera from anti-Jo-1-positive patients with polymyositis and interstitial lung disease induce expression of intercellular adhesion molecule 1 in human lung endothelial cells. 9 38
19644880 2009
8
Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. 9 38
18628284 2009
9
Eosinophilic myositis in calpainopathy: could immunosuppression of the eosinophilic myositis alter the early natural course of the dystrophic disease? 9 38
19285864 2009
10
[Hypothyroidism with leading myopathy in a patient suffering from systemic lupus erythematosus and Hashimoto's thyroiditis]. 9 38
18936898 2008
11
Distal inflammatory myopathy: unusual presentation of polymyositis or new entity? 9 38
18534849 2008
12
Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. 9 38
18420712 2008
13
Adults with eosinophilic myositis and calpain-3 mutations. 9 38
18299526 2008
14
Transcriptional explorations of CAPN3 identify novel splicing mutations, a large-sized genomic deletion and evidence for messenger RNA decay. 9 38
17979987 2007
15
NOGO is increased and binds to BACE1 in sporadic inclusion-body myositis and in A beta PP-overexpressing cultured human muscle fibers. 9 38
17764014 2007
16
Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. 9 38
17277004 2007
17
[Is every case of muscle damage during hypolipemic therapy the side effect of this therapy? A case report]. 9 38
18320790 2007
18
Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. 9 38
17763431 2007
19
Rituximab for refractory polymyositis: an open-label prospective study. 9 38
17722224 2007
20
Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis. 9 38
17665459 2007
21
Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. 9 38
17606177 2007
22
Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in UK. 9 38
17405833 2007
23
Expression of major histocompatibility complex class I and class II antigens in canine masticatory muscle myositis. 9 38
17360184 2007
24
Inducible overexpression of wild-type prion protein in the muscles leads to a primary myopathy in transgenic mice. 9 38
17420473 2007
25
Myostatin precursor protein is increased and associates with amyloid-beta precursor protein in inclusion-body myositis culture model. 9 38
17359364 2007
26
Genetic determinants of statin intolerance. 9 38
17376224 2007
27
Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. 9 38
17265504 2007
28
MyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscle. 9 38
17077152 2006
29
HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre. 9 38
17057271 2006
30
Elevated levels of amyloid precursor protein in muscle of patients with amyotrophic lateral sclerosis and a mouse model of the disease. 9 38
16856153 2006
31
Presymptomatic neuromuscular disorders disclosed following statin treatment. 9 38
16864763 2006
32
Parkin and its association with alpha-synuclein and AbetaPP in inclusion-body myositis and AbetaPP-overexpressing cultured human muscle fibers. 9 38
17039976 2006
33
CAPN3 mutations in patients with idiopathic eosinophilic myositis. 9 38
16607617 2006
34
Neurological manifestations of dengue virus infection. 9 38
16524594 2006
35
Serum creatine kinase levels and renal function measures in exertional muscle damage. 9 38
16679975 2006
36
Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. 9 38
16431335 2006
37
Antisynthetase syndrome associated with sarcoidosis. 9 38
17043379 2006
38
Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis. 9 38
16224247 2005
39
Role of major histocompatibility complex class I molecules in autoimmune myositis. 9 38
16224250 2005
40
Mdm muscular dystrophy: interactions with calpain 3 and a novel functional role for titin's N2A domain. 9 38
16115818 2005
41
Safety and efficacy of rosuvastatin therapy for the prevention of hyperlipidemia in adult cardiac transplant recipients. 9 38
16102434 2005
42
Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. 9 38
16052580 2005
43
Myostatin is increased and complexes with amyloid-beta within sporadic inclusion-body myositis muscle fibers. 9 38
15983828 2005
44
Benign acute childhood myositis. 9 38
15973022 2005
45
Changes of single fiber electromyography in patients with inflammatory myopathies. 9 38
15844301 2005
46
Do tissue levels of autoantigenic aminoacyl-tRNA synthetase predict clinical disease? 9 38
16085368 2005
47
Annexin expression in inflammatory myopathies. 9 38
15221885 2004
48
Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. 9 38
14983103 2004
49
Pathogenesis of myositis and myasthenia associated with titin and ryanodine receptor antibodies. 9 38
14592894 2003
50
Transthyretin Val122Ile, accumulated Abeta, and inclusion-body myositis aspects in cultured muscle. 9 38
12874414 2003

Variations for Myositis

ClinVar genetic disease variations for Myositis:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 FAM111B NM_198947.4(FAM111B): c.1462del (p.Cys488fs) deletion Likely pathogenic 11:58893032-58893032 11:59125559-59125559

Expression for Myositis

Search GEO for disease gene expression data for Myositis.

Pathways for Myositis

GO Terms for Myositis

Cellular components related to Myositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Z disc GO:0030018 9.33 TTN DMD CAPN3
2 extracellular exosome GO:0070062 9.28 TTN SERPINA3 PSMB9 PIK3C2A MB ICOSLG
3 astrocyte projection GO:0097449 8.96 DMD APP

Biological processes related to Myositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet degranulation GO:0002576 9.54 TTN SERPINA3 APP
2 muscle organ development GO:0007517 9.5 MSTN DMD CAPN3
3 response to muscle activity GO:0014850 9.4 MSTN CAPN3
4 muscle fiber development GO:0048747 9.26 DYSF DMD
5 astrocyte activation GO:0048143 9.16 BACE2 APP
6 skeletal muscle tissue regeneration GO:0043403 9.13 MSTN DYSF DMD
7 muscle cell cellular homeostasis GO:0046716 8.8 MSTN DMD CAPN3

Molecular functions related to Myositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of muscle GO:0008307 8.8 TTN DMD CAPN3

Sources for Myositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....